ZELVARA

Indication: ZELVARA® (celdatuzumab-mkrz) is indicated, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative, claudin 18.2 (CLDN18.2)-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Dosing & Administration

ZELVARA is administered as an intravenous infusion with weight-based dosing calculated using body surface area (BSA). A loading dose is given on Cycle 1 Day 1, followed by maintenance dosing every 3 weeks.

Dosing Calculator

Enter weight and height to calculate dose

BSA calculated using the Mosteller formula: BSA (m²) = √((height × weight) / 3600). For informational purposes only — verify all calculations independently.

Recommended Dosing Schedule

CycleDoseRouteDurationNotes
Cycle 1, Day 1800 mg/m²IV infusion~3.5 hoursAdminister premedication 30 minutes prior
Cycle 2+, Day 1600 mg/m²IV infusion~2.5 hoursContinue until disease progression or unacceptable toxicity

Recommended Premedication

MedicationDoseRouteTiming
Dexamethasone12 mgIV30 minutes before infusion
Ondansetron8 mgIV30 minutes before infusion
Diphenhydramine25-50 mgIV or PO30 minutes before infusion (optional)

Dose Modification Guidelines

ToxicityGradeAction
Nausea/VomitingGrade 3Withhold until ≤Grade 1. Resume at 600 mg/m² (or 400 mg/m² if already reduced).
Nausea/VomitingGrade 4 or recurrent Grade 3Permanently discontinue ZELVARA.
Infusion-Related ReactionGrade 1-2Interrupt infusion. Resume at 50% reduced rate upon resolution.
Infusion-Related ReactionGrade 3-4Permanently discontinue ZELVARA.
Other nonhematologicGrade 3Withhold until ≤Grade 1. Resume at same or reduced dose per clinical judgment.
Other nonhematologicGrade 4Permanently discontinue ZELVARA.